Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. METHODS: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1-12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. RESULTS: Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01-2.41; aOR 2.43, 95% CI 1.48-4.02) and ICU admission (aOR 2.30, 95% CI 0.98-5.39; aOR 3.93, 95% CI 1.56-9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54-10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29-2.38; aOR 2.76, 95% CI 1.87-4.07) and ICU admission (aOR 2.55, 95% CI 1.49-4.36; aOR 4.32, 95% CI 2.27-8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09-12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13-3.07; aOR 2.88, 95% CI 1.68-4.92) and ICU admission (aOR 2.13, 95% CI 0.85-5.35; aOR 3.23, 95% CI 1.17-8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71-17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. DISCUSSION: Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Luna, G., Alping, P., Burman, J., Fink, K., Fogdell-Hahn, A., Gunnarsson, M., Hillert, J., Langer-Gould, A., Lycke, J., Nilsson, P., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3365 · Cited by 521 · cited 2×
“Disease-modifying therapies (DMTs) that act by immunomodulatory/immunosuppressive mechanisms are a mainstay of treatment of multiple sclerosis (MS) but can increase infection susceptibility.(1) Cross-sectional(2) and cohort(3-5)”
BackgroundSelf-citationSafavi, F., Nourbakhsh, B., & Azimi, A. R. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102195 · Cited by 140
Montero-Escribano, P., Matías-Guiu, J., Gómez-Iglesias, P., Porta-Etessam, J., Pytel, V., & Matias-Guiu, J. A. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102185 · Cited by 128
Cited by
Autoimmune Encephalitis Misdiagnosis in Adults
Flanagan, E. P., Geschwind, M. D., Lopez-Chiriboga, A. S., Blackburn, K. M., Turaga, S., Binks, S., Zitser, J., Gelfand, J. M., Day, G. S., Dunham, S. R., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4251 · Cited by 303
Inhibition of CD40L with frexalimab in multiple sclerosis
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Truffinet, P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309439 · Cited by 102
Bruton’s tyrosine kinase inhibition in multiple sclerosis
Schneider, R., & Oh, J. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01229-z · Cited by 47
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
Metadata
- Authors
- Simpson-Yap, S., De Brouwer, E., Kalincik, T., Rijke, N., Hillert, J. A., Walton, C., Edan, G., Moreau, Y., Spelman, T., Geys, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A., Ardeshirdavanai, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., Bergmann, A. B., Braune, S., Stahmann, A., Middleton, R., Salter, A., Fox, R. J., van der Walt, A., Butzkueven, H., Alroughani, R., Ozakbas, S., Rojas, J. I., van der Mei, I., Nag, N., Ivanov, R., Sciascia do Olival, G., Dias, A. E., Magyari, M., Brum, D., Mendes, M. F., Alonso, R. N., Nicholas, R. S., Bauer, J., Chertcoff, A. S., Zabalza, A., Arrambide, G., Fidao, A., Comi, G., & Peeters, L.
- Venue
- Neurology
- Published
- 2021-11-09
- Volume
- 97
- Issue
- 19
- Pages
- e1870-e1885
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3204061559
- Cited by
- 236
- References
- 4
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0000000000012753
- The paper
- Simpson-Yap, S., De Brouwer, E., Kalincik, T., Rijke, N., Hillert, J. A., Walton, C., Edan, G., Moreau, Y., Spelman, T., Geys, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A., Ardeshirdavanai, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., . . . Peeters, L. (2021). Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis. Neurology. https://doi.org/10.1212/wnl.0000000000012753
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.